NINLARO® (Ixazomib)

The FDA on November 20, 2015 approved NINLARO® in combination with Lenalidomide and Dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO® is the first approved oral proteasome inhibitor and is a product of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.